Latira

Quick links to important sections

Latira

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Latira

Latira is a prescription-only (Rx) fixed-combination drug administered as a sterile ophthalmic solution (eye drops), classified as an Ophthalmic Glaucoma Agent. This medication is explicitly designed for topical ocular use to manage pathologically elevated intraocular pressure (IOP). The fixed-combination approach is clinically recognized for simplifying the therapeutic regimen, which can lead to improved medication adherence for patients managing chronic conditions.

Quick Facts

Property Description
Active ingredients Latanoprost, Timolol maleate
Form Sterile ophthalmic solution (Eye drops)
Pharmacological class Prostaglandin F2α Analog & Beta-adrenergic Receptor Blocker
Common use Reduction of elevated intraocular pressure
Origin Synthetic

Composition and Dual Pharmacological Classification

Latira's composition is defined by its two distinct, synthetic active ingredients: Latanoprost and Timolol maleate. These components belong to two major pharmacological classes that work together to maximize pressure reduction: Latanoprost is a Prostaglandin F2α analog, while Timolol maleate is a non-selective Beta-adrenergic receptor blocker (beta-blocker). This singular formulation is a key differentiator, reducing the need for separate instillations for the adult patient.

General Purpose and Synergistic Effect

The general purpose of Latira is to achieve a potent ocular hypotensive effect for the management of elevated intraocular pressure in conditions like ocular hypertension and chronic open-angle glaucoma. This preparation is typically utilized for adult patients whose condition is insufficiently responsive to monotherapy with either a prostaglandin analog or a beta-blocker alone. The combination offers a synergistic effect, where the combined pressure-lowering result exceeds the sum of the individual effects, ensuring robust maintenance of lower pressure levels.

What side effects are possible with Latira?

The official safety documentation for Latira (lurasidone) identifies specific serious risks and outlines adverse reactions by frequency and body system.

Official Safety Restrictions

  • Increased Mortality in Elderly Patients with Dementia-Related Psychosis: The drug carries a Boxed Warning regarding an increased risk of death when used to treat psychosis in elderly patients with dementia, for which this medicine is not approved.
  • Suicidal Thoughts and Behaviors: A Boxed Warning is included concerning the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) using antidepressant drugs, which includes this class of medicine.
  • Contraindications: Use is strictly restricted in patients with a known hypersensitivity to the drug. It is also contraindicated for use with strong inhibitors (e.g., ketoconazole) or strong inducers (e.g., rifampin) of the CYP3A4 enzyme, as this may dangerously alter drug levels.

Serious and Clinically Significant Adverse Reactions

Official regulatory sources highlight serious risks categorized as Warnings and Precautions:

  • Neuroleptic Malignant Syndrome (NMS): A potentially fatal, rare complex of symptoms reported with antipsychotics.
  • Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary movements, with risk increasing with the duration of treatment.
  • Metabolic Changes: Monitoring is required for significant metabolic alterations, including hyperglycemia (high blood sugar) that may lead to diabetes, dyslipidemia (abnormal cholesterol/fat levels), and weight gain.
  • Cerebrovascular Adverse Events: Elderly patients with dementia-related psychosis face an increased risk of cerebrovascular events, such as stroke.
  • Hematologic Effects: Cases of Leukopenia, Neutropenia, and Agranulocytosis (decreased white blood cell counts) have been reported.
  • Orthostatic Hypotension and Syncope: Risk of dizziness or fainting due to a sudden drop in blood pressure upon standing, particularly early in treatment.

Commonly Observed Adverse Reactions

In clinical trials, commonly observed adverse reactions (incidence 5% and at least twice the rate for placebo) included somnolence (sleepiness), akathisia (inner restlessness or urge to move), extrapyramidal symptoms (involuntary movement or muscle stiffness), and nausea.

Overdose and Emergency Response

Latira Overdose and When to Seek Help

Suspected overdose of Latira is primarily defined by the systemic effects resulting from the absorption of the Timolol (beta-blocker) component, as documented in regulatory labeling. The potential for systemic effects is associated with accidental oral ingestion or excessive topical ocular absorption of the sterile solution.


Overdose Scope

Documented overdose presentations: Presentations include bradycardia (slow heart rate), hypotension (low blood pressure), overt cardiac failure, and bronchospasm. High topical exposure may also result in conjunctival hyperemia (ocular redness).

Physiological systems affected: The cardiovascular system and respiratory system are the primary physiological systems affected by documented overdose, with the potential for fatal bronchospasm and cardiac failure resulting in death.

Emergency-response statements: Immediate medical attention must be sought if overdose is suspected or confirmed. Urgent medical help is required for any signs of severe systemic effects, particularly those indicative of severe cardiac or respiratory distress.


Overdose Management

Official overdose statements: Management involves administering symptomatic and supportive treatment. No specific antidote is known for the Latanoprost component. Due to the potential for severe, life-threatening outcomes such as cardiogenic shock, hospital monitoring and close observation for signs of cardiac failure are required as per official regulatory guidance.

Therapeutic Uses of Latira

What Latira Treats: Main Uses and Benefits

Latira is commonly used across conditions presenting with acute episodes of specific mental health disorders. The medicine is relevant for addressing conditions characterized by periods of heightened symptoms, primarily schizophrenia (in adults and adolescents aged 13 and over) and major depressive episodes associated with Bipolar I Disorder (bipolar depression), where it may be part of symptomatic management. Its application is relevant when supportive symptom management is appropriate for these disorders.

Latira may assist with symptoms related to heightened physiological activity and helps address symptom clusters that may become intense or disruptive, often used during phases when symptoms become more noticeable. This approach generally contributes to easing the overall symptom load. It also contributes to improved comfort during periods of heightened symptoms, and may help patients cope more steadily. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. It supports patients during episodes of heightened discomfort and provides supportive relief when symptoms interfere with routine activities.

“...provides support that helps ease the overall symptom burden and assists with maintaining functional stability.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Who can and cannot use Latira?

Eligibility for Latira (latanoprost and timolol maleate ophthalmic solution) is strictly defined by regulatory authorities and is determined by age, medical history, and pre-existing conditions, primarily due to the timolol (beta-blocker) component.

Latira is approved for adult patients (aged 18 and older) who have chronic open-angle glaucoma or ocular hypertension that has not been adequately controlled by a single-agent eye drop (monotherapy).


Contraindicated Populations

Latira must not be used by individuals with the following absolute contraindications:

  • Respiratory Conditions: Bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease (COPD).
  • Cardiac Conditions: Sinus bradycardia (slow heart rate), second or third-degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock.
  • Hypersensitivity: Known allergy to latanoprost, timolol maleate, or any other component in the solution.

Limitations by Age and Status

Population Regulatory Status
Pediatrics (Under 18) Safety and effectiveness have not been established; use is not recommended.
Pregnancy Should not be used unless determined clearly necessary by a physician.
Lactation Not recommended due to potential excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Latira, a fixed-combination ophthalmic solution, has documented interactions that are primarily pharmacodynamic in nature, stemming from the systemic absorption of the Timolol component and local ocular effects of the Latanoprost component. All documented interaction information is based strictly on regulatory labeling.

Documented Pharmacodynamic Interactions

Co-administration with oral beta-adrenergic receptor blockers may result in an additive systemic beta-blockade. Furthermore, additive systemic effects, such as hypotension and bradycardia, may occur when combined with oral calcium channel blockers, anti-arrhythmics, digitalis glycosides, or parasympathomimetics. The co-administration of adrenergic psychotropic agents or epinephrine is noted to carry a risk of mydriasis (pupil dilation).

Interaction-Related Restrictions

Co-administration with other topical ophthalmic prostaglandin analogs is restricted because official regulatory documents state it can lead to a paradoxical increase in intraocular pressure (IOP), counteracting the desired pressure-lowering effect. There are no restrictions documented in the labeling regarding interactions with food, alcohol, or common herbal products.

Administration Timing Rule

When co-administered with any other topical ophthalmic drugs, regulatory documents require that they must be administered at least five minutes apart to prevent dilution of the first administered drug and maintain consistent exposure.

Mechanism of Action

How Latira Works

Latira exerts its effect through a synergistic dual-action mechanism, targeting both the inflow and outflow of intraocular fluid to achieve the combined physiological effect.


Facilitating Fluid Drainage via the Uveoscleral Outflow Pathway

The Latanoprost component selectively activates the Prostaglandin F receptors (FP receptors) located in the ciliary muscle. This molecular activation triggers a specific signal cascade that results in the remodeling of the Extracellular Matrix (ECM). This process alters the integrity and increases the spacing of the tissue structure, thereby decreasing the flow resistance and increasing the conductance of the aqueous humor through the non-conventional uveoscleral pathway.


Suppressing Fluid Production via beta-Adrenergic Receptor Blockade

The Timolol maleate component acts as a non-selective antagonist, binding to and blocking beta1 and beta2 adrenergic receptors found on the ciliary epithelium. This blockade interrupts the natural sympathetic nervous system signals that stimulate the production process. The resulting inhibition of the adenylate cyclase cascade leads to a substantial reduction in the rate of aqueous humor formation by the ciliary body.

Dosage and Administration Information

How to use Latira (Lurasidone)

The administration of Latira is based on specific procedural parameters to ensure proper systemic absorption and dosing alignment with patient physiology. The medicine is administered orally, and a requirement for its use is that it must be taken once daily with food. Specifically, the parameter specifies that the dose should be taken with a meal or snack providing at least 350 calories. The tablet itself is intended to be swallowed whole.

Administration Parameter Parameters
Route & Frequency Oral, once daily administration.
Schizophrenia Dose (Adults) Maximum dose is 160 mg per day.
Bipolar Depression Dose (Adults) Maximum dose is 120 mg per day (Monotherapy or Adjunctive use).

The usage guidelines involve specific dose modifications for certain populations. Patients with moderate or severe renal impairment or moderate hepatic impairment require a restricted maximum dose of 80 mg per day. For those with severe hepatic impairment, the maximum daily dose is reduced to 40 mg per day. Additionally, the maximum dose for pediatric patients (aged 10–17) is restricted to 80 mg per day across approved indications. The administration protocol also limits use with certain coadministered drugs, and coadministration with strong inhibitors of the CYP3A4 metabolic pathway is restricted. For all patients, periodic re-evaluation for continued treatment is recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Latira (Lurasidone)

Evidence for Managing Acute Symptoms in Schizophrenia

The clinical research for Latira in this context was mainly conducted using multiple short-term, randomized, placebo-controlled trials (RCTs). These studies were designed to evaluate the medicine during periods of heightened symptom activity and typically lasted for about six weeks. Researchers examined adult patients experiencing acute episodes of schizophrenia and also conducted separate trials that included adolescents aged 13 to 17 years. Studies examined how symptoms were measured and tracked over time.

Studies monitored overall symptom severity, using standardized tools such as the PANSS (Positive and Negative Syndrome Scale). This scale helped researchers track outcomes related to both the more active symptoms and those related to functional imbalance. Studies monitored measured changes in these symptom scores and global illness assessments (CGI-S) over the defined time intervals. The findings reported measured changes in scores when compared to a placebo group.

What remains uncertain is the need for controlled, long-term data. The follow-up durations were limited in the pivotal acute studies, which means the initial evidence is largely focused on the first six weeks of use. While longer-term open-label studies have been conducted, long-term effects are not fully established by placebo-controlled research for use beyond this initial acute phase.

Evidence for Major Depressive Episodes in Bipolar I Disorder

This evidence was gathered through similar short-term (six-week), placebo-controlled RCTs. Studies examined the medicine in two main ways: as a standalone therapy (monotherapy) and as an adjunctive therapy, meaning it was used alongside existing medications like lithium or valproate. This research was also extended to include separate trials for children and adolescents (age 10 to 17 years) in monotherapy.

The research examined outcomes related to depressive symptom severity, primarily measured using the Montgomery–Åsberg Depression Rating Scale (MADRS). Studies monitored the evolution of symptoms in the observed populations, and findings reported measured changes in these depressive scales when compared to a placebo group. Researchers also tracked functional outcomes and monitored for potential changes in manic symptoms to ensure overall mood stability.

A key limitation is that this research does not cover the treatment of the manic phase of Bipolar Disorder; it was studied solely for the depressive episodes. As with schizophrenia, controlled follow-up durations were limited to the initial six-week period, and the long-term data relies more on less-controlled, extended observational studies.

Frequently Asked Questions (FAQ)

Common questions about Latira (FAQ)


Q: How quickly do the effects of Latira typically begin?

According to official product information for psychiatric use, clinical improvement may begin within the first few days to weeks. While some changes in specific symptoms may be noted early on, full therapeutic effect may not be fully established until around six weeks, as examined in clinical trials.

Q: How long does one dose of Latira stay in the system?

Regulatory information indicates that the drug (Lurasidone) is removed from the body relatively slowly. The elimination half-life, which is the time it takes for half of the drug to be cleared, is approximately 18 hours. The medicine reaches steady levels in the body after about seven days of consistent use.

Q: Can Latira be used by people who have mild health issues?

Official labeling does not specifically address 'mild' health issues, but it lists clear dose adjustments or restrictions for severe conditions affecting the heart, lungs, liver, and kidneys. It is important that the healthcare provider is aware of all current health problems before the medicine is started.

Q: Does Latira affect the way other common daily vitamins or supplements work?

The drug is processed by a specific enzyme in the body called CYP3A4. Although general vitamins are not typically listed as interactions, some supplements or herbal products can change how this enzyme works, potentially leading to altered drug levels. Any supplement in question can be reviewed against the product information by a healthcare provider.

Q: What is the risk classification of Latira (e.g., Schedule X, Controlled Substance)?

According to regulatory agencies, Latira (Lurasidone) is not classified as a controlled substance by the U.S. Drug Enforcement Agency (DEA). This means it does not fall under specific regulations for drugs that carry a high potential for abuse or dependence.

Q: If I miss a dose of Latira, what do official documents suggest I do?

Official patient guidance indicates that taking a missed dose as soon as it is remembered is one approach. However, if it is close to the time of the next scheduled dose, the missed dose is usually skipped entirely. The guidance emphasizes avoiding taking two doses at once.

Q: What is a 'contraindication' for Latira, and why is it important?

A contraindication is a situation or medical condition that strictly advises against the use of a medicine. Official labeling lists contraindications because using the medicine under these conditions carries a risk of complications or worsening a pre-existing medical issue, such as severe respiratory or cardiac problems.

Q: Why does Latira require a specific method of use (e.g., must be taken with water)?

The oral tablets are manufactured as film-coated pills and designed to be swallowed whole to prevent a bitter taste. They must be taken with food of at least 350 calories to ensure the correct amount of medicine is absorbed by the body to be effective.

Q: Does taking Latira impact the ability to drive or operate machinery?

Official patient information warns that the drug can cause side effects like drowsiness, which may affect attention and coordination. Due to the potential for impairment, engaging in activities such as driving or operating machinery is not recommended until the medicine's effect on performance is known.

Q: Does Latira interact with common antibiotics?

Yes, regulatory documents indicate that Latira (Lurasidone) is restricted or requires dose modification when taken with antibiotics that are strong or moderate inhibitors of the CYP3A4 enzyme. Examples of these include certain macrolide or antifungal antibiotics, which can lead to dangerously high drug levels.

Q: Are there genetic factors mentioned in research that might affect how Latira works?

Studies examining how the drug is processed in different populations have noted differences in drug exposure based on ethnicity. For example, some regulatory data indicated that subjects of Asian descent may have a higher concentration of the drug in their blood compared to Caucasian subjects.

Q: How does the drug manufacturer describe the taste or texture of Latira?

The oral tablets are manufactured as film-coated pills. This coating is intended to prevent the patient from tasting the medicine, as the uncoated compound is known to have a bitter taste.

Q: What happens if Latira is taken past its expiration date?

Official guidance advises patients to never use the medicine after the expiry date shown on the packaging. Past this date, the effectiveness, stability, and safety of the drug cannot be guaranteed. For safe disposal, it is recommended to consult a pharmacist.

Q: Are there reports of Latira causing dependency or withdrawal symptoms?

The drug is not legally classified as having abuse potential or causing physical dependence. However, healthcare experts warn that abruptly stopping the medicine can lead to withdrawal effects. Discontinuation of the drug is typically managed slowly under medical guidance.

Q: What are the general rules for stopping Latira according to official guidance?

Official guidance emphasizes avoiding abrupt discontinuation or dose changes without supervision. To minimize the risk of withdrawal symptoms and maintain overall health stability, the medicine is typically slowly reduced (tapered) under the supervision of a healthcare professional.

Q: Is Latira prescribed only by specialists, or by general practitioners too?

Official guidance often recommends that medication for psychiatric conditions, such as Latira (Lurasidone), should be initiated by a specialist service. While continuation of the prescription may sometimes be managed in primary care, local restrictions often guide the level of involvement required from the prescriber.

Q: Does research show differences in Latira's effects based on gender?

Official research data reviewed subgroups based on gender, and the analysis of these groups did not reveal clear evidence of a differential response to the drug. This suggests that the medication's effects are generally consistent across genders examined in the trials.

Q: What are the initial symptoms that usually indicate Latira is starting to work?

Official patient information indicates that initial signs of the medicine taking effect may include general improvements such as more stable mood, clearer thoughts, and decreased agitation. These positive changes are expected to become noticeable within the first one to two weeks of treatment.

Q: What does the patient information leaflet say about overdose symptoms for Latira?

According to official overdose management information, there is no specific antidote for Lurasidone toxicity. In the event of an overdose, management involves supportive care focusing on maintaining the patient's breathing, oxygen levels, and treating symptoms such as low blood pressure.

Q: Is it possible for Latira to interact with herbal supplements like St. John's Wort?

Yes, official prescribing information advises caution with St. John's wort. This herbal product is known to interfere with the same CYP3A4 enzyme that processes the drug. This can significantly lower the concentration of Latira (Lurasidone), potentially reducing its effectiveness.

Q: Do the side effects of Latira usually lessen over time?

Side effects from many medications, including Latira, tend to be most noticeable when first starting treatment or after a dose change. While some side effects may lessen as the body adjusts, it is appropriate to consult a provider if any side effects persist or become bothersome.

Q: Does Latira interfere with birth control effectiveness?

Official documents do not specifically state that the drug interferes with the effectiveness of hormonal birth control. However, the medicine can cause a hormonal change that affects the menstrual cycle. A discussion of potential risks and interactions with a doctor is appropriate for patients using any type of birth control.

How should Latira be stored and disposed of?

How to Store and Dispose of Latira?

Latira (latanoprost/timolol ophthalmic solution) must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness.


Storage Requirements

Unopened bottles must be stored under refrigeration at 2 C to 8 C (36 F to 46 F) and must not be frozen. To ensure protection from light, the bottle should remain in its original outer carton.

Once opened, the solution may be stored at room temperature, but not above 25 C (77 F). The contents must be discarded six weeks after the first opening.


Disposal and Child Safety

All medicine, including Latira, must be kept out of the sight and reach of children and pets. Unused or expired medication should not be flushed down the toilet or poured down a drain. For proper disposal, consult a pharmacist or local drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Latira found in:

A-Z Index: